{"schema_version":"secwatch.filing_event.v1","accession":"0001730463-25-000032","form_type":"8-K","ticker":"AUTL","cik":"0001730463","company_name":"Autolus Therapeutics plc","filed_at":"2025-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.504415+00:00","generated_at":"2026-05-22T04:57:41.101157+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Autolus reports Q1 AUCATZYL revenue $9.0M; UK MHRA approval for r/r B-ALL","bullets":["Q1 2025 AUCATZYL net product revenue $9.0M, first quarter of launch.","UK MHRA granted conditional marketing authorization for AUCATZYL in r/r B-ALL.","Net loss $70.2M ($0.26 per share) vs $52.7M ($0.24) in Q1 2024.","Cash & marketable securities $516.6M; company well-capitalized for launch and trials.","Phase 1 CARLYSLE data: 3/6 SLE patients complete renal response; Phase 2 LN trial by year-end."],"urls":{"canonical":"https://secwatch.observer/filing/0001730463-25-000032","json":"https://secwatch.observer/filing/0001730463-25-000032.json","markdown":"https://secwatch.observer/filing/0001730463-25-000032.md","text":"https://secwatch.observer/filing/0001730463-25-000032.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1730463/000173046325000032/0001730463-25-000032-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1730463/000173046325000032/autl-20250508.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T04:57:41.101157+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}